Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucotuzumab celmoleukin

Next Previous
X
Search
Drug Profile

Tucotuzumab celmoleukin

Alternative Names: EMD-273066; huKS-IL2; KS-IL2; KS-interleukin-2

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Lexigen
  • Developer EMD Lexigen; Merck KGaA
  • Class Antineoplastics; Cytokines; Immunoglobulin fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 15 Aug 2017 EMD Serono terminates a phase II trial in Ovarian cancer because the trial got cancelled and no subjects signed informed consent form in USA (Parenteral) (NCT00408967)
  • 28 Feb 2009 Tucotuzumab celmoleukin is still in phase II development for small cell lung cancer
  • 28 Feb 2009 Discontinued - Phase-II for Ovarian cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top